Conclusion
Nonserious infections occur frequently in patients with RA, and predictors mirror those reported with serious infections. All bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large, and a relationship between nonserious infection and targeted immunomodulatory therapy likely exists.
Refer to the full study for all source material.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Excerpted and adapted from: Bechman K, Halai K, Yates M, et al. Nonserious infections in patients with rheumatoid arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Oct;73(10).